What Arrowhead Pharmaceuticals promised, and what happened

Guidance Tracker · every commitment management made on a call, tracked from the quarter it was made

Guidance

What management said, and what became of it

14 of 16 judged targets kept · 21 open · verdicts reflect calls analysed to Jun 2026.

Target	Original wording	Said	Latest call	Verdict
PCSK9/APOC3 dimer clinical entry	Enter the clinic	Jun 2024	Jun 2026:Also in cardiometabolic, the ARO-DIMER-PA Phase I/IIa study in patients with mixed hyperlipidemia is nearing full enrollment, and we plan to share top line data in September. Call transcript, Jun 2026 · no direct link	Achieved
ARO-DIMER-PA interim data	Report interim data	Dec 2025	Jun 2026:the first clinical readout of ARO-DIMER-PA, the first dual functional siRNA candidate targeting both PCSK9 and APOC3 for LDL and TG lowering is expected in September. Call transcript, Jun 2026 · no direct link	On Track

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

The full ledger

Open Arrowhead Pharmaceuticals’s full ledger

A free account opens 5 company ledgers a month. All 37 tracked commitments, with each call’s wording and source.

US Pro opens 100 a month, first month free →

The rest of the ledger

Pro opens all 37 tracked commitments for Arrowhead Pharmaceuticals

Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

Upgrade to Pro, one month free